N-803与厄达替尼在卡介苗无反应性非肌肉浸润性膀胱癌中的比较
Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
作者信息
Gupta Anusha, Verma Shiv, Gupta Sanjay
机构信息
Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Faculty of Science Program, University of Western Ontario, London, ON N6A 5A5, Canada.
出版信息
Cancers (Basel). 2024 Oct 11;16(20):3445. doi: 10.3390/cancers16203445.
Abstract
Bladder cancer, the sixth most common cancer and the tenth leading cause of cancer-related death worldwide, remains a significant global health concern [...].
摘要
膀胱癌是全球第六大常见癌症，也是癌症相关死亡的第十大主要原因，仍然是一个重大的全球健康问题[……]
相似文献
1
Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.N-803与厄达替尼在卡介苗无反应性非肌肉浸润性膀胱癌中的比较
Cancers (Basel). 2024 Oct 11;16(20):3445. doi: 10.3390/cancers16203445.
2
Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.卡介苗无应答性非肌肉浸润性膀胱癌：定义和未来的治疗策略。
Int J Urol. 2020 Feb;27(2):108-116. doi: 10.1111/iju.14153. Epub 2019 Dec 3.
3
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.日本接受早期根治性膀胱切除术的卡介苗无反应性非肌肉浸润性膀胱癌患者的预后预测。
Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13.
4
A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.关于卡介苗无反应性原位癌及不符合根治性膀胱切除术条件或拒绝根治性膀胱切除术患者肿瘤的可用治疗方式的系统评价。
SAGE Open Med. 2023 Mar 16;11:20503121231160408. doi: 10.1177/20503121231160408. eCollection 2023.
5
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.卡介苗无应答非肌肉浸润性膀胱癌的新兴免疫治疗选择。
J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1.
6
Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.卡介苗治疗失败后膀胱癌的临床和临床前治疗方法
J Urol. 2023 Jan;209(1):32-48. doi: 10.1097/JU.0000000000002957. Epub 2022 Sep 6.
7
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.卡介苗无反应性非肌层浸润性膀胱癌患者的膀胱保留治疗：长期生存结果分析
Eur Urol Open Sci. 2023 May 13;53:16-22. doi: 10.1016/j.euros.2023.04.013. eCollection 2023 Jul.
8
Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.单剂量即刻化疗联合辅助诱导卡介苗治疗高危非肌层浸润性膀胱癌患者可降低复发和进展风险。
Int J Urol. 2022 Aug;29(8):867-875. doi: 10.1111/iju.14926. Epub 2022 May 16.
9
Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.卡介苗治疗非肌肉浸润性膀胱癌患者的当代结局：对临床试验设计的启示。
J Urol. 2021 Jun;205(6):1612-1621. doi: 10.1097/JU.0000000000001633. Epub 2021 Jan 27.
10
Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.预测卡介苗免疫治疗和卡介苗失败对非肌肉浸润性膀胱癌反应的生物标志物。
Int J Urol. 2022 Aug;29(8):807-815. doi: 10.1111/iju.14921. Epub 2022 May 22.
引用本文的文献
1
Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.诺加彭德金α英巴奇普-pmln（安克蒂瓦）联合卡介苗：卡介苗无反应性非肌肉浸润性膀胱癌干预的有前景的武器。
Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.
本文引用的文献
1
Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.2020 年和 2040 年根据 GLOBOCAN 估计的膀胱癌死亡率全球负担。
World J Urol. 2024 Apr 16;42(1):237. doi: 10.1007/s00345-024-04949-8.
2
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
3
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.非肌层浸润性膀胱癌的诊断与治疗：美国泌尿外科学会/泌尿外科学会指南：2024年修订版
J Urol. 2024 Apr;211(4):533-538. doi: 10.1097/JU.0000000000003846. Epub 2024 Jan 24.
4
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.厄达替尼治疗卡介苗治疗后的高危非肌肉浸润性膀胱癌。
Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21.
5
Current and emerging therapies for neuroendocrine prostate cancer.神经内分泌前列腺癌的现有和新兴疗法。
Pharmacol Ther. 2022 Oct;238:108255. doi: 10.1016/j.pharmthera.2022.108255. Epub 2022 Jul 26.
6
Possible drawbacks of relying only on molecular testing for diagnosing SARS-CoV-2 infections.仅依靠分子检测诊断新冠病毒感染的潜在弊端。
Public Health. 2022 Apr;205:e2. doi: 10.1016/j.puhe.2021.09.035. Epub 2021 Oct 5.
7
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect.BCG 在膀胱癌治疗中的作用机制：当前认识与展望。
Biomed Pharmacother. 2020 Sep;129:110393. doi: 10.1016/j.biopha.2020.110393. Epub 2020 Jun 16.
8
Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors.膀胱内灌注卡介苗治疗非肌层浸润性膀胱移行细胞癌的复发与进展：单中心经验及预后因素分析
Urol Ann. 2016 Jul-Sep;8(3):333-7. doi: 10.4103/0974-7796.184891.
Zotero 插件